The goal of this observational study is to study the safety of initiation of antitumortherapy early after nucleic acid test turn negativity in tumor patients infected withCOVID-19. The main questions aims to answer are: - Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. - Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. - How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patientsParticipants will be asked to answer the question about: - the severity and duration of COVID-19 symptoms - the date of diagnosis of COVID-19 - the date of negative nucleic acid test - the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy
Not Provided
Inclusion Criteria:
- Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022
to May 31.
- COVID-19 was confirmed by antigen testing or nucleic acid testing.
- Tumor was confirmed by pathology.
- Patients received systemic antitumor therapy after infected with COVID-19.
Exclusion Criteria:
- COVID-19 was not confirmed by antigen testing or nucleic acid testing
- Tumor was not confirmed by pathology
- Patients did not receive systemic antitumor therapy
- Patients died before receiving systemic antitumor therapy
Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, China
Investigator: Xiaofen Pan, MD
Contact: +8618124671750
panxf8@mail.sysu.edu.cn
Xiaofen Pan, MD
+8618124671750
panxf8@mail.sysu.edu.cn
Bo Wang, MD
0755-81206796
wangb68377@sina.com
Bo Wang, Principal Investigator
The Seventh Affiliated Hospital of Sun Yat-sen University